Lataa...
Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease
Alzheimer’s disease (AD) affects more than twenty-five million people worldwide and is the most common form of dementia. Symptomatic treatments have been developed, but effective intervention to alter disease progression is needed. Targets have been identified for disease-modifying drugs, but the re...
Tallennettuna:
| Julkaisussa: | J Neural Transm |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4305447/ https://ncbi.nlm.nih.gov/pubmed/22354745 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00702-012-0772-4 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|